biostudies-literatureWei ZNational Natural Science Foundation of China (NSFC) Youth Science FundBasic Research Program of Jiangsu ProvinceLeading Major Projects in Basic Research at the Forefront of the Institute (China)National Science and Technology Major ProjectSocial Development Plan of Jiangsu Provincial Department of Science and Technology (China)National Key Research and Development Program of ChinaMajor Special Projects of Jiangsu Provincial Department of Science and Technology (China)343https://www.ebi.ac.uk/biostudies/studies/S-EPMC12369064biostudies-literatureUnknown24(1)Patients with type 2 diabetes (T2D) and hypertension are at increased risk of adverse cardiovascular (CV) events. However, real-world evidence comparing the CV effectiveness and safety of major hypoglycemic drug classes remains limited in this population. This multicenter pooled analysis aims to directly compare the CV outcomes and safety profiles of these key agents in patients with T2D and hypertension. We analyzed electronic health records from two databases in a cohort study of T2D patients with hypertension who had initiated metformin as first-line therapy. Propensity score matching (PSM) and Cox proportional hazards models were used to compare the risks of 3-/4-point major adverse cardiovascular events (MACE) and safety outcomes across drug classes added to metformin: insulin, sulfonCardiovascular diabetologyComparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis.PMC12369064BE2023781QY202403BK202413082024ZD05318002023YFC3605800BK2024305482404291Liu YLi JTian YZhang XJing SShen SWei ZWang YXu WWang ZLiu WQin CfalseComparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis.Patients with type 2 diabetes (T2D) and hypertension are at increased risk of adverse cardiovascular (CV) events. However, real-world evidence comparing the CV effectiveness and safety of major hypoglycemic drug classes remains limited in this population. This multicenter pooled analysis aims to directly compare the CV outcomes and safety profiles of these key agents in patients with T2D and hypertension. We analyzed electronic health records from two databases in a cohort study of T2D patients with hypertension who had initiated metformin as first-line therapy. Propensity score matching (PSM) and Cox proportional hazards models were used to compare the risks of 3-/4-point major adverse cardiovascular events (MACE) and safety outcomes across drug classes added to metformin: insulin, sulfon2025-01-01T00:00:00Z2025 Aug2026-05-07T05:02:43.055Z2026-04-07T22:33:33.347ZS-EPMC123690644083629910.1186/s12933-025-02892-5